Form 4: Lexaria Bioscience Corp. Executive Acquires Stock Options
SEC Form 4 Filing
Vanessa Carle, Secretary of Lexaria Bioscience Corp., reports acquisition of stock options.
Summary
- On April 26, 2024, Vanessa Carle, Secretary of Lexaria Bioscience Corp., reported a transaction involving derivative securities.
- Carle acquired 10,000 stock options with an exercise price of $2.36, exercisable from April 26, 2024, to April 26, 2029.
- Following the transaction, Carle directly owns 62,567 stock options.
- Carle also directly owns 67 common shares and 67 warrants.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard disclosure of stock option acquisition.
Industry Context
This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their transactions in the company's securities.
Key Dates
| Date | Description |
|---|---|
| 11/13/2019 | Date of Warrants |
| 04/26/2021 | Date of Stock Options |
| 06/08/2021 | Date of Stock Options |
| 09/01/2021 | Date of Stock Options |
| 08/29/2022 | Date of Stock Options |
| 05/09/2023 | Shareholder approval received for repricing of stock options |
| 10/26/2023 | Date of Stock Options |
| 04/26/2024 | Date of Earliest Transaction and acquisition of stock options |
| 04/26/2024 | Date of Stock Options |
| 05/10/2024 | Signature Date |
| 11/13/2024 | Expiration Date of Warrants |
| 04/26/2026 | Expiration Date of Stock Options |
| 06/08/2026 | Expiration Date of Stock Options |
| 09/01/2026 | Expiration Date of Stock Options |
| 08/29/2027 | Expiration Date of Stock Options |
| 10/26/2028 | Expiration Date of Stock Options |
| 04/26/2029 | Expiration Date of Stock Options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.